Alfuzosin hydrochloride , ≥98% , 81403-68-1

Synonym(s):
Alfuzosin hydrochloride;N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide hydrochloride;Uroxatral hydrochloride

CAS NO.：81403-68-1

Empirical Formula: C19H28ClN5O4

Molecular Weight: 425.91

MDL number: MFCD00879135

EINECS: 620-512-3

PRODUCT Properties

• Melting point: 225°C
• storage temp.: 2-8°C
• solubility: DMSO: >10mg/mL
• pka: 8.13(at 25℃)
• form: solid
• color: White to Off-White
• Merck: 14,238
• CAS DataBase Reference: 81403-68-1(CAS DataBase Reference)

Description and Uses

Alfuzosin (SL-77499) (I), a quinazoline derivative which is a uroselective alpha-1 adrenoreceptor antagonist, has been developed and launched worldwide by Sanofi-Synthelabo, for the treatment of benign prostate hyperplasia (BPH). In November 2003, alfuzosin (I) was launched as an extended release formulation in the US as Uroxatral utilizing Skyepharma’s oral controlled release technology.

Antihypertensor;Alpha 1- adrenergic antagonist

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P264-P270-P301+P312-P330-P501
• Hazard Codes: Xn
• Risk Statements: 22
• WGK Germany: 3
• RTECS: LT9965475
• HS Code: 2934990002